share_log

EyePoint Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

EyePoint Pharmaceuticals | 144：擬議出售證券

美股SEC公告 ·  01/11 13:00
牛牛AI助理已提取核心訊息
Ocumension Therapeutics, a director at EyePoint Pharmaceuticals, Inc., is set to sell 1,910,500 shares of common stock on 01/11/2024, with an aggregate market value of approximately $37,159,225. The shares were originally acquired on 12/31/2020 through a private placement by EyePoint Pharmaceuticals. This transaction follows a previous sale of 1,000,000 shares by Ocumension Therapeutics in the past three months, which grossed $19,510,637.
Ocumension Therapeutics, a director at EyePoint Pharmaceuticals, Inc., is set to sell 1,910,500 shares of common stock on 01/11/2024, with an aggregate market value of approximately $37,159,225. The shares were originally acquired on 12/31/2020 through a private placement by EyePoint Pharmaceuticals. This transaction follows a previous sale of 1,000,000 shares by Ocumension Therapeutics in the past three months, which grossed $19,510,637.
EyePoint Pharmicals, Inc. 的董事Ocumension Therapeutics定於2024年11月1日出售1,910,500股普通股，總市值約爲37,159,225美元。這些股票最初是在2020年12月31日通過EyePoint Pharmicals的私募收購的。該交易是在Ocumension Therapeutics在過去三個月中出售了100萬股股票之後進行的，總收入爲19,510,637美元。
EyePoint Pharmicals, Inc. 的董事Ocumension Therapeutics定於2024年11月1日出售1,910,500股普通股，總市值約爲37,159,225美元。這些股票最初是在2020年12月31日通過EyePoint Pharmicals的私募收購的。該交易是在Ocumension Therapeutics在過去三個月中出售了100萬股股票之後進行的，總收入爲19,510,637美元。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。